» Articles » PMID: 14695164

Optic Nerve Glioma in Mice Requires Astrocyte Nf1 Gene Inactivation and Nf1 Brain Heterozygosity

Overview
Journal Cancer Res
Specialty Oncology
Date 2003 Dec 26
PMID 14695164
Citations 150
Authors
Affiliations
Soon will be listed here.
Abstract

Whereas biallelic neurofibromatosis 1 (NF1) inactivation is observed in NF1-associated gliomas, astrocyte-restricted Nf1 conditional knockout mice do not develop gliomas. These observations suggest that NF1 glioma formation requires additional cellular or genetic conditions. To determine the effect of an Nf1 heterozygous brain environment on NF1 glioma formation, we generated Nf1+/- mice lacking Nf1 expression in astrocytes. In contrast to astrocyte-restricted Nf1 conditional knockout mice, Nf1+/- mice lacking Nf1 in astrocytes develop optic nerve gliomas. This mouse model demonstrates that Nf1+/- cells contribute to the pathogenesis of gliomas in NF1 and provides a tool for the preclinical evaluation of potential therapeutic interventions for these tumors.

Citing Articles

Human single cell RNA-sequencing reveals a targetable CD8 exhausted T cell population that maintains mouse low-grade glioma growth.

Barakat R, Chatterjee J, Mu R, Qi X, Gu X, Smirnov I Nat Commun. 2024; 15(1):10312.

PMID: 39609412 PMC: 11605098. DOI: 10.1038/s41467-024-54569-4.


Maternal obesogenic diet operates at the tumor cell of origin to increase incidence and decrease latency of neurofibromatosis type 1 optic pathway glioma.

Chan A, Zhang K, Martin G, Bano S, Chatterjee J, Mahto S Neuro Oncol. 2024; 26(12):2339-2351.

PMID: 39023130 PMC: 11630557. DOI: 10.1093/neuonc/noae136.


An Overview of Optic Pathway Glioma With Neurofibromatosis Type 1: Pathogenesis, Risk Factors, and Therapeutic Strategies.

Chen Y, Yu J, Ge S, Jia R, Song X, Wang Y Invest Ophthalmol Vis Sci. 2024; 65(6):8.

PMID: 38837168 PMC: 11160950. DOI: 10.1167/iovs.65.6.8.


Nf1 mutation disrupts activity-dependent oligodendroglial plasticity and motor learning in mice.

Pan Y, Hysinger J, Yalcin B, Lennon J, Byun Y, Raghavan P Nat Neurosci. 2024; 27(8):1555-1564.

PMID: 38816530 PMC: 11303248. DOI: 10.1038/s41593-024-01654-y.


Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.

Miyagishima K, Qiao F, Stasheff S, Nadal-Nicolas F Vision (Basel). 2024; 8(2).

PMID: 38804352 PMC: 11130890. DOI: 10.3390/vision8020031.